| Literature DB >> 23285055 |
Xavier Waltz1, Aurélien Pichon, Nathalie Lemonne, Danièle Mougenel, Marie-Laure Lalanne-Mistrih, Yann Lamarre, Vanessa Tarer, Benoit Tressières, Maryse Etienne-Julan, Marie-Dominique Hardy-Dessources, Olivier Hue, Philippe Connes.
Abstract
BACKGROUND/AIM: Although it has been hypothesized that muscle metabolism and fatigability could be impaired in sickle cell patients, no study has addressed this issue.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23285055 PMCID: PMC3527490 DOI: 10.1371/journal.pone.0052471
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subjects characteristics, hematological and hemorheological parameters in healthy subjects (AA) and patients with sickle cell-hemoglobin C disease (SC) or sickle cell anemia (SS).
| AA | SC | SS | |
|
| 34.6±12.5 | 35.5±12.3 | 32.9±13.5 |
|
| 90.8±9.2 | 88.9±11.9 | 84.8±8.3 |
|
| 99.6±0.7 | 99.2±1.0 | 95.8±3.0†* |
|
| 3.2±1.0 | 3.1±1.3 | 2.8±1.4 |
|
| 0.4±0.6 | 1.2±0.8 | 6.8±5.6*† |
|
| – | 47.4±0.9 | 83.8±6.1* |
|
| – | 43.4±1.3 | – |
|
| 6.3±2.1 | 7.4±2.5 | 11.3±3.2*† |
|
| 4.60±0.52 | 4.35±0.80 | 2.88±0.43*† |
|
| 13.5±1.3 | 11.1±1.2* | 8.4±1.1*† |
|
| 42.0±3.4 | 32.5±2.8* | 24.9±4.3*† |
|
| 1.1±0.5 | 2.5±1.6 | 8.4±3.3*† |
|
| 248±58 | 311±171 | 403±119* |
|
| 6.3±1.0 | 7.9±1.2* | 6.3±1.6† |
|
| 0.59±0.02 | 0.43±0.05* | 0.34±0.12*† |
|
| 64.6±7.2 | 43.2±9.4* | 52.5±10.6*† |
|
| 146±43 | 295±128* | 394±172* |
Values represent mean ± S.D. MAP = mean arterial pressure, SpO2 = transcutaneus oxygen saturation, SATT = skin+adipose tissue thickness, ηb = blood viscosity, EI = Elongation Index (i.e., RBC deformability). Different from AA (*p<0.05); different from SC (†p<0.05).
Muscle force and fatigability (i.e., force decrease) in healthy subjects (AA) and patients with sickle cell-hemoglobin C disease (SC) patients or sickle cell anemia (SS).
| AA | SC | SS | |
|
| 8 (3/5) | 7 (3/4) | 8 (3/5) |
|
| 18.2±3.0 | 14.9±3.5* | 13.2±2.5* |
|
| 0.60±0.26 | 0.46±0.10 | 0.35±0.10 |
|
| 14.4±3.0† | 12.0±2.3† | 11.1±1.8*† |
|
| 0.64±0.30 | 0.46±0.10 | 0.39±0.10 |
|
| 22.0±6.0 | 18.4±4.4 | 17.2±7.7 |
Values represent mean ± S.D. n (M/F) = sample size (male/female), pre-MVC = maximal voluntary contraction before isometric handgrip exercise, post-MVC = maximal voluntary contraction after isometric handgrip exercise, force decrease = percentage of maximal voluntary contraction decrease after exercise, RMS = root mean square. Post-MVC of SC patients tended to be lower than AA subjects (p = 0.07). Different from AA group (*p<0.05); different from pre-MVC (†p<0.05).
Figure 1Muscle microvascular oxygen saturation (TOI) at rest in AA, SC and SS groups.
Different from AA group (*p<0.05); different from SC group (†p<0.05).
Figure 2Forearm blood flow at rest (2a) and muscle oxygen consumption at rest (2b) in AA, SC and SS groups.
Figure 3Fast Fourier Transform analysis of TOI signal variability.
Total power spectral density (3a, flowmotion activity), power spectral density in interval I, II and III (3b, vasomotion activity), power spectral density in interval IV, V (3c) and normalized spectral density (3d). Interval I = endothelial activity and/or nitric oxide metabolism, interval II = nervous sympathetic activity of the vessel wall, interval III = myogenic activity, interval IV = breathing frequency and interval V heart rate and cardiac output.
Figure 4Example of Fast Fourier Transform analysis of TOI signal variability in one AA subject (left), one SC patient (middle) and one SS patient (right).
The frequency axis is divided into three parts: vasomotion activity (left), interval IV (middle), and interval V (right). Note that the scale of the Y-axis is different for the three subjects.